PriceTargets.com logo

Orchard Therapeutics - ORTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $42.33
  • Forecasted Upside: 726.82%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.12 As of 03/23/2023 01:00 AM ET
▲ +0.1 (1.99%)

This chart shows the closing price for ORTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orchard Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORTX

Analyst Price Target is $42.33
▲ +726.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Orchard Therapeutics in the last 3 months. The average price target is $42.33, with a high forecast of $50.00 and a low forecast of $37.00. The average price target represents a 726.82% upside from the last price of $5.12.

This chart shows the closing price for ORTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Orchard Therapeutics. This rating has held steady since January 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2023OppenheimerBoost Target$5.00 ➝ $37.00Low
11/15/2022Cantor FitzgeraldReiterated RatingOverweightLow
5/13/2022BarclaysLower Target$60.00 ➝ $40.00High
4/1/2022Sumitomo Mitsui Financial GroupReiterated RatingOutperform ➝ NeutralMedium
3/31/2022Stifel NicolausLower Target$120.00 ➝ $50.00Medium
3/31/2022CowenDowngradeOutperform ➝ Market PerformHigh
2/11/2022Stifel NicolausReiterated RatingBuyLow
12/30/2021Cantor FitzgeraldInitiated CoverageOverweight$120.00 ➝ $90.00High
11/16/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
11/5/2021OppenheimerLower TargetOutperform$150.00 ➝ $130.00Medium
10/18/2021Cantor FitzgeraldReiterated RatingOverweightMedium
8/18/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
6/30/2021JPMorgan Chase & Co.Lower TargetOverweight$150.00 ➝ $140.00High
6/30/2021Cantor FitzgeraldLower TargetOverweight$170.00 ➝ $120.00High
5/17/2021OppenheimerReiterated RatingBuy$170.00Low
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight$140.00 ➝ $150.00N/A
3/2/2021JPMorgan Chase & Co.Boost TargetOverweight$140.00 ➝ $150.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$120.00High
1/6/2021Cantor FitzgeraldInitiated CoverageOverweight$160.00N/A
9/14/2020OppenheimerLower TargetOutperform$260.00 ➝ $160.00High
6/1/2020OppenheimerInitiated CoverageBuyHigh
5/22/2020JPMorgan Chase & Co.Lower TargetOverweight$260.00 ➝ $170.00Medium
5/7/2020OppenheimerReiterated RatingBuy$260.00High
4/1/2020OppenheimerLower TargetOutperform$290.00 ➝ $280.00Medium
12/2/2019CowenReiterated RatingBuy$280.00Medium
11/6/2019CowenReiterated RatingBuy$280.00High
9/17/2019GuggenheimInitiated CoverageBuy$310.00Low
9/15/2019CowenInitiated CoverageBuy$270.00Medium
9/5/2019BarclaysInitiated CoverageOverweight$210.00Low
9/4/2019CowenReiterated RatingBuy$270.00Low
8/29/2019OppenheimerInitiated CoverageOutperform$260.00High
3/22/2019WedbushReiterated RatingOutperform$250.00High
12/17/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$180.00 ➝ $210.00High
12/2/2018WedbushInitiated CoverageOutperform$250.00 ➝ $168.00Medium
11/26/2018WedbushInitiated CoverageOutperform ➝ Outperform$250.00 ➝ $250.00Medium
11/26/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$250.00Medium
11/26/2018CowenInitiated CoverageOutperform$270.00Medium
11/26/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$180.00Medium
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/25/2022
  • 2 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
Mentions as of
9/24/2022
  • 6 very positive mentions
  • 34 positive mentions
  • 9 negative mentions
  • 4 very negative mentions
Mentions as of
10/24/2022
  • 1 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
Mentions as of
11/23/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
1/22/2023
  • 2 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
Mentions as of
2/21/2023
  • 10 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 10 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Orchard Therapeutics logo
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $5.12
Low: $5.01
High: $5.22

50 Day Range

MA: $5.46
Low: $4.58
High: $6.50

52 Week Range

Now: $5.12
Low: $3.60
High: $8.33

Volume

37,488 shs

Average Volume

121,021 shs

Market Capitalization

$64.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Orchard Therapeutics?

The following Wall Street sell-side analysts have issued reports on Orchard Therapeutics in the last twelve months: Barclays PLC, Cantor Fitzgerald, Cowen Inc, Oppenheimer Holdings Inc., Stifel Nicolaus, and Sumitomo Mitsui Financial Group, Inc..
View the latest analyst ratings for ORTX.

What is the current price target for Orchard Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Orchard Therapeutics in the last year. Their average twelve-month price target is $42.33, suggesting a possible upside of 726.8%. Stifel Nicolaus has the highest price target set, predicting ORTX will reach $50.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $37.00 for Orchard Therapeutics in the next year.
View the latest price targets for ORTX.

What is the current consensus analyst rating for Orchard Therapeutics?

Orchard Therapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORTX, but not buy more shares or sell existing shares.
View the latest ratings for ORTX.

What other companies compete with Orchard Therapeutics?

Other companies that are similar to Orchard Therapeutics include Compugen, TScan Therapeutics, Black Diamond Therapeutics, Passage Bio and X4 Pharmaceuticals. Learn More about companies similar to Orchard Therapeutics.

How do I contact Orchard Therapeutics' investor relations team?

Orchard Therapeutics' physical mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company's listed phone number is 442038088286 and its investor relations email address is [email protected] The official website for Orchard Therapeutics is www.orchard-tx.com. Learn More about contacing Orchard Therapeutics investor relations.